New drug NM6603 enters first human tests for advanced cancers

NCT ID NCT07292038

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called NM6603 in about 30 adults with advanced solid tumors (mainly colorectal or triple-negative breast cancer) who have run out of standard options. The main goal is to find the safest dose and check how the drug moves through the body. Participants receive the drug and are monitored closely for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center (SYSUCC)

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, Fujian, 361001, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450052, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••